tiprankstipranks
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Holding PCRX?
Track your performance easily

Pacira Pharmaceuticals (PCRX) Ownership - Who Owns Pacira Pharmaceuticals?

353 Followers

Pacira Pharmaceuticals (PCRX) Ownership Overview

1.55%31.93%16.45%40.00%10.08%
16.45% Other Institutional Investors
40.00% ETFs
10.08% Public Companies and
Individual Investors
The ownership structure of Pacira Pharmaceuticals (PCRX) stock is a mix of institutional, retail, and individual investors. Approximately 88.37% of the company’s stock is owned by Institutional Investors, 1.55% is owned by Insiders, and 10.08% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 19, 2024
xxxxxxxxxxxxx
$20034
Aug 19, 2024
Laura Brege
Director
xxxxxxxxxxxxx
$12810
Aug 14, 2024
xxxxxxxxxxxxx
$25800
Aug 13, 2024
Frank D. Lee
Ceo,director
xxxxxxxxxxxxx
$99994

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
5,478,471Institution11.87%91,654,820
4,866,062Institution10.54%81,409,217
4,745,476Institution10.28%79,391,813
3,892,506Institution8.43%65,121,625
1,262,745Institution2.73%21,125,724
1,048,353Institution2.27%17,538,946
961,535Institution2.08%16,086,481
835,477Institution1.81%13,977,530
673,569Institution1.46%11,268,809
650,482Institution1.41%10,882,564

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
3,892,506Institution8.43%65,121,625
1,262,745Institution2.73%21,125,724
1,048,353Institution2.27%17,538,946
673,569Institution1.46%11,268,809
650,482Institution1.41%10,882,564
509,850Institution1.10%8,529,791
501,401Institution1.09%8,388,439
379,008Institution0.82%6,340,804
359,128Institution0.78%6,008,211
356,312Institution0.77%5,961,100

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
4,862,396Institution10.53%80,715,774
2,951,008Institution6.39%49,370,364
1,247,635Institution2.70%20,872,934
1,374,530Institution2.98%20,686,677
1,098,474Institution2.38%16,532,034
743,008Institution1.61%11,182,270
720,238Institution1.56%10,839,582
639,600Institution1.39%10,642,944
469,867Institution1.02%7,860,875
417,669Institution0.90%6,950,012

FAQ

Who Owns Pacira Pharmaceuticals (PCRX)?
According to the latest TipRanks data, approximately 16.45% of the company's stock is held by institutional investors, 1.55% is held by insiders, and 10.08% is held by retail investors.
    What percentage of Pacira Pharmaceuticals (PCRX) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 16.45% of Pacira Pharmaceuticals (PCRX) stock is held by institutional investors.
      What percentage of Pacira Pharmaceuticals (PCRX) stock is held by retail investors?
      According to the latest TipRanks data, approximately 10.08% of Pacira Pharmaceuticals (PCRX) stock is held by retail investors.
        Who owns the most shares of Pacira Pharmaceuticals (PCRX)?
        iShares owns the most shares of Pacira Pharmaceuticals (PCRX).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis